Long-term outcome and predictors of remission in Behçet’s disease in daily practice

References

• Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, et al. Behçet's disease-a contemporary review. J Autoimmun. 2009;32(3-4):178–88.
   PubMed Web of Science ®Google Scholar
• Zeidan MJ, Saadoun D, Garrido M, Klatzmann D, Six A, Cacoub P. Behçet’s disease physiopathology: a contemporary review. Auto Immun Highlights. 2016;7(1):4–15.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Wechsler B, Desseaux K, Le Thi Huong D, Amoura Z, Resche-Rigon M, et al. Mortality in Behçet's disease . Arthritis Rheum. 2010;62(9):2806–12.
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet’s disease. Semin Arthritis Rheum. 1998;27(4):197–217.
   PubMed Web of Science ®Google Scholar
• Bayraktar Y, Ozaslan E, Van Thiel DH. Gastrointestinal manifestations of Behçet’s disease. J Clin Gastroenterol. 2000;30(2):144–54.
   PubMed Web of Science ®Google Scholar
• Cho SB, Cho S, Bang D. New insights in the clinical understanding of Behçet's disease. Yonsei Med J. 2012;53(1):35–42.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behçet’s disease-review and basis for recommendations . Rheumatology. 2007;46(5):736–41.
   PubMed Web of Science ®Google Scholar
• Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA. Behçet’s disease: comparing 3 decades of treatment response at the national eye institute. Can J Ophthalmol. 2008;43(4):468–72.
   PubMed Web of Science ®Google Scholar
• D'Angelo S, Leccese P, Padula A, Nigro A, Gilio M. Predictive factors for the response to infliximab therapy in patients with Behcet's disease. ACR/ARHP Annual Meeting. Boston, MA; 2014.
   Google Scholar
• Onal S, Kazokoglu H, Koc A, Akman M, Bavbek T, Direskeneli H, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis . Arch Ophthalmol. 2011;129(3):288–94.
   PubMed Web of Science ®Google Scholar
• Kavandi H, Khabbazi A, Kolahi S, Hajialilo M, Shayan FK, Oliaei M. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behçet’s disease. Clin Rheumatol. 2016;35(11):2765–9.
   PubMed Web of Science ®Google Scholar
• Taylor SR, Singh J, Menezo V, Wakefield D, McCluskey P, Lightman S. Behçet disease: visual prognosis and factors influencing the development of visual loss. Am J Ophthalmol. 2011;152(6):1059–66.
   PubMed Web of Science ®Google Scholar
• Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease . Arthritis Rheum. 2010;62(9):2796–805.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomata H, Nose Y. Prognostic factors of vision in patients with Behçet disease. Ophthalmology. 1995;102(2):317–21.
   PubMed Web of Science ®Google Scholar
• Celiker H, Kazokoglu H, Direskeneli H. Factors affecting relapse and remission in Behçet’s uveitis treated with interferon alpha2a. J Ocul Pharmacol Ther. 2019;35(1):58–65.
   PubMed Web of Science ®Google Scholar
• International Team for the Revision of the International Criteria for Behçet’s Disease. Evaluation of the international criteria for Behçet’sdisease (ICBD). Clinic Exp Rheumatol 2006;24(Suppl. 42):S13.
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Akbarian M, Shahram F, Tebbi M, Chams C, Chams H. Iran Behçet’s disease dynamic activity measure. Abstracts of the XIIth European congress of rheumatology. Hungarian Rheumatol 1991;32:134.
   Google Scholar
• Lawton G, Bhakta B, Chamberlain M, Tennant A. The Behçet’s disease activity indexBehçet’s . Rheumatology. 2004;43(1):73–8.
   PubMed Web of Science ®Google Scholar
• Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum.1997;40(2):371–80.
   PubMed Web of Science ®Google Scholar
• Shahram F, Khabbazi A, Nadji A, Ziaie N, Tehrani Banihashemi A, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behçet’s disease. Mod Rheumatol.2009;19(5):536–41.
   PubMed Web of Science ®Google Scholar
• Steiman AJ, Urowitz MB, Ibañez D, Papneja A, Gladman DD. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808–16.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behçet’s disease in Greece. Clin Exp Rheumatol. 2003;21(4):S19–S26.
   PubMed Web of Science ®Google Scholar
• Noel N, Bernard R, Wechsler B, Resche-Rigon M, Depaz R, Le Thi Huong Boutin D, et al. Long-term outcome of neuro-Behçet's disease. Arthritis Rheumatol. 2014;66(5):1306–14.
   PubMed Web of Science ®Google Scholar
• Bonitsis NG, Luong Nguyen LB, LaValley MP, Papoutsis N, Altenburg A, Kötter I, et al. Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature . Rheumatology. 2015;54(1):121–33.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center . Medicine. 2003;82(1):60–76.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shahram F, Chams H, Nadji A, Jamshidi AR, Chams C, et al. The influence of gender on the severity and the outcome of ocular lesions in Behçet’s disease. Adv Exp Med Biol. 2003;528:67–71.
   PubMed Web of Science ®Google Scholar
• Khabbazi A, Noshad H, Shayan FK, Kavandi H, Hajialiloo M, Kolahi S. Demographic and clinical features of Behçet’s disease in AzerbaijanBehçet’s . Int J Rheum Dis. 2018;21(5):1114–9.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, et al. Risk and prognostic factors of poor visual outcome in Behçet’s disease with ocular involvement. Graefe's Arch Clin Exp Ophthalmo. 2005;243(11):1147–52.
   PubMed Web of Science ®Google Scholar
• Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behçet's disease. Yonsei Med J. 2013;54(5):1084–90.
   PubMed Web of Science ®Google Scholar
• Zou J, Ji DN, Cai JF, Guan JL, Bao ZL. Long-term outcomes and predictors of sustained response in patients with intestinal Behçet’s disease treated with infliximab. . Dig Dis Sci. 2017;62(2):441–7.
   PubMed Web of Science ®Google Scholar
• Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behçet’s disease. Inflamm Bowel Dis. 2012;18(6):1064–71.
   PubMed Web of Science ®Google Scholar
• Malek Mahdavi A, Khabbazi A, Yaaghoobian B, Ghojazadeh M, Agamohammadi R, Kheyrollahiyan A, et al. Cigarette smoking and risk of Behçet’s disease: a propensity score matching analysis. Mod Rheumatol. 2019;29(4):633–9.
   PubMed Web of Science ®Google Scholar
• Soy M, Erken E, Konca K, Ozbek S. Smoking and Behçet's disease . Clin Rheumatol. 2000;19(6):508–9.
   PubMed Web of Science ®Google Scholar
• Aramaki K, Kikuchi H, Hirohata S. HLA-B51 and cigarette smoking as risk factors for chronic progressive neurological manifestations in Behçet’s disease. Mod Rheumatol. 2007;17(1):81–2.
   PubMedGoogle Scholar
• Bilgin AB, Turkoglu EB, Ilhan HD, Unal M, Apaydin KC. Is smoking a risk factor in ocular Behçet Disease? Ocul Immunol Inflamm. 2015;23(4):283–6.
   PubMed Web of Science ®Google Scholar
• Khabbazi A, Karkon Shayan F, Ghojazadeh M, Kavandi H, Hajialiloo M, Esalat Manesh K, et al. Adherence to treatment in patients with Behçet's disease. Int J Rheum Dis. 2018;21(12):2158–66.
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575–8.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, Nagafuchi H, Kuwana M, Takeno M, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Behçet’s disease. J Neurol Sci. 2015;349(1-2):143–8.
   PubMed Web of Science ®Google Scholar
• Park J, Cheon JH, Park Y, Park SJ, Kim IT, Kim WH. Efficacy and tolerability of methotrexate therapy for refractory intestinal Behçet's disease: a single center experience. Intest Res. 2018;16(2):315–8.
   PubMed Web of Science ®Google Scholar
• Barešić M, Reih M, Habek M, Vukojević N, Anić N. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab. Rheumatol Int. 2018;38(7):1301–6.
   PubMed Web of Science ®Google Scholar
• Tognon S, Graziani G, Marcolongo R. Anti-TNF-alpha therapy in seven patients with Behçet’s uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007;1110:474–84.
   PubMed Web of Science ®Google Scholar
• Zlatanović G, Jovanović S, Veselinović D, Zivković M. Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behçet’s disease and HLA B51 positive vasculitis. Vojnosanit Pregl. 2012;69(2):168–74.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Shams H, Shahram F, Nadji A, Chams-Davatchi C, Sadeghi Abdollahi B, et al. Methotrexate in ocular manifestations of Behçet’s disease: a longitudinal study up to 15 years. Int J Rheum Dis. 2013;16(5):568–77.
   PubMed Web of Science ®Google Scholar